Protecting effects of vasonatrin peptide against carbon tetrachloride-induced liver fibrosis

Regulatory Peptides

Volumn 164, Issue 2-3, 2010, Pages 139-143

  Chen, Bao Ying ^a   Qu, Ping ^b   Tie, Ru ^b   Zhu, Miao Zhang ^b   Zhu, Xiao Xing ^b   Yu, Jun ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic fibrosis; Hepatic stellate cells; Natriuretic peptides

Indexed keywords

8 BROMO CYCLIC GMP; ATRIAL NATRIURETIC FACTOR RECEPTOR; CARBON TETRACHLORIDE; COLLAGEN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DNA; EOSIN; HEMATOXYLIN; HS 142 1; KT 5823; NATRIURETIC FACTOR; PROLINE; THYMIDINE; UNCLASSIFIED DRUG; VASONATRIN PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; IN VITRO STUDY; INTRACELLULAR SPACE; LIVER CELL CULTURE; LIVER FIBROSIS; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARBAZOLES; CARBON TETRACHLORIDE; CELL LINE; COLLAGEN; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; PROTEIN KINASE INHIBITORS; RATS;

MUS;

EID: 77955846053     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.06.007     Document Type: Article

References (20)

1. Brenner D.A. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009, 120:361-368.
2. Mas V.R., Fisher R.A., Archer K.J., Maluf D.G. Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics 2009, 6:421-431.
3. Friedman S.L. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993, 328:1828-1835.
4. Boerrigter G., Costello-Boerrigter L.C., Burnett J.C. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin 2009, 5:501-514.
5. Wei C.M., Kim C.H., Miller V.M., Burnett J.C. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993, 92:2048-2052.
6. Morishita Y., Sano T., Ando K., Saitoh Y., Kase H., Yamada K., Matsuda Y. Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun 1991, 176:949-957.
7. Woodard G.E., Li X., Brown J., Rosado J.A. Receptor subtypes for vasonatrin peptide in renal glomeruli and arteries. Regul Pept 2005, 129:183-189.
8. Sengenès C., Zakaroff-Girard A., Moulin A., Berlan M., Bouloumié A., Lafontan M., Galitzky J. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol 2002, 283:R257-R265.
9. Nakatsuji H., Maeda N., Hibuse T., Hiuge A., Hirata A., Kuroda Y., Kishida K., Kihara S., Funahashi T., Shimomura I. Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun 2010, 392:100-105.
10. Ishigaki N., Yamamoto N., Jin H., Uchida K., Terai S., Sakaida I. Continuos intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat. Biochem Biophys Res Commun 2009, 378:354-359.
11. Junqueira L.C., Bignolas G., Brentani R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979, 11:447-455.
12. Lu S.Y., Zhu M.Z., Wang D.S., Chen S.Y., Zhang W.D., Dong H., Yu J., Guo H.T. Inhibition of the proliferation of smooth muscle cells from human coronary bypass vessels by vasonatrin peptide. Physiol Res 2004, 53:387-393.
13. Yu J, Zhu M, Fu Z, Zhu X, Zhao Y, Chen B. Vasorelaxing action of vasonatrin peptide is associated with activation of large-conductance Ca2+-activated potassium channels in vascular smooth muscle cells. Physiol Res 2009. [Electronic publication ahead of print].
14. Lu S.Y., Wang D.S., Zhu M.Z., Zhang Q.H., Hu Y.Z., Pei J.M. Inhibition of hypoxia-induced proliferation and collagen synthesis by vasonatrin peptide in cultured rat pulmonary artery smooth muscle cells. Life Sci 2005, 77:28-38.
15. Yu J., Feng H.S., Chen B.Y., Qu P., Liu L.B., Chen J.K., Tie R., Huang X.J., Zhao Y.F., Zhu X.X., Zhu M.Z. Protective effects of vasonatrin peptide against hypobaric hypoxia-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2010, 37:69-74.
16. Tao J., Mallat A., Gallois C., Belmadani S., Méry P.F., Nhieu J.T., Pavoine C., Lotersztajn S. Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells. J Biol Chem 1999, 274:23761-23769.
17. Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
18. Nishikimi T., Iemura-Inaba C., Akimoto K., Ishikawa K., Koshikawa S., Matsuoka H. Stimulatory and Inhibitory regulation of lipolysis by the NPR-A/cGMP/PKG and NPR-C/G(i) pathways in rat cultured adipocytes. Regul Pept 2009, 153:56-63.
19. Tanaka T., Tsutamoto T., Sakai H., Nishiyama K., Fujii M., Yamamoto T., Horie M. Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur J Heart Fail 2008, 10:360-366.
20. Feng H.S., Zang Y.M., Zhu M.Z., Pei J.M., Wang Y.M., Wang L., Shi P.T. Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide. Sheng Li Xue Bao 1999, 51:515-520.